Literature DB >> 24742479

Association of a polymorphism in a gene encoding a urate transporter with CKD progression.

Alessandra Testa1, Francesca Mallamaci1, Belinda Spoto1, Anna Pisano1, Maria Cristina Sanguedolce1, Giovanni Tripepi1, Daniela Leonardis1, Carmine Zoccali2.   

Abstract

BACKGROUND AND OBJECTIVES: Hyperuricemia predicts a high risk for CKD progression but there is no large clinical trial in humans indicating that this relationship is causal in nature. The rs734553 single-nucleotide polymorphism (SNP) of the GLUT9 urate transporter gene was strongly associated with uric acid (UA) levels in a large meta-analysis. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This prospective study adopted the Mendelian randomization approach. The rs734553 SNP was used as an instrumental variable to investigate the relationship between UA and renal outcomes in a cohort of 755 patients with CKD who were enrolled between October 18, 2005, and October 2, 2008. The association between the polymorphism and UA was preliminary confirmed in a series of 211 healthy volunteers enrolled between January 1, 2001, and July 12, 2011, from the same geographic area as the patients with CKD. The study end point was a composite renal-end point (i.e., >30% decrease in the GFR, dialysis, or transplantation). Patients were followed up for a median of 36 months.
RESULTS: In healthy individuals, serum UA levels were highest in homozygotes for the T allele (risk allele), intermediate in heterozygotes for the same allele, and lowest in those without the risk allele (P<0.001), but no such relationship was found in patients with CKD. In the CKD cohort, homozygotes (TT) and heterozygotes (GT) for the risk allele had a 2.35 times higher risk (hazard ratio, 2.35; 95% confidence interval, 1.25 to 4.42; P=0.008) of CKD progression. The risk for CKD progression by rs734553 remained unmodified in analyses adjusting for proteinuria, GFR, and other classical and CKD-peculiar risk factors.
CONCLUSIONS: A GLUT9 polymorphism, which is strongly associated with serum UA levels in healthy individuals of the general population with normal renal function, holds a strong predictive power for CKD progression. These findings are compatible with the hypothesis that the link between UA and CKD progression is causal in nature.
Copyright © 2014 by the American Society of Nephrology.

Entities:  

Keywords:  CKD progression; epidemiology; polymorphisms; uric acid

Mesh:

Substances:

Year:  2014        PMID: 24742479      PMCID: PMC4046734          DOI: 10.2215/CJN.11041013

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  32 in total

1.  Effect of allopurinol in chronic kidney disease progression and cardiovascular risk.

Authors:  Marian Goicoechea; Soledad García de Vinuesa; Ursula Verdalles; Caridad Ruiz-Caro; Jara Ampuero; Abraham Rincón; David Arroyo; José Luño
Journal:  Clin J Am Soc Nephrol       Date:  2010-06-10       Impact factor: 8.237

2.  APOL1 risk variants, race, and progression of chronic kidney disease.

Authors:  Afshin Parsa; W H Linda Kao; Dawei Xie; Brad C Astor; Man Li; Chi-yuan Hsu; Harold I Feldman; Rulan S Parekh; John W Kusek; Tom H Greene; Jeffrey C Fink; Amanda H Anderson; Michael J Choi; Jackson T Wright; James P Lash; Barry I Freedman; Akinlolu Ojo; Cheryl A Winkler; Dominic S Raj; Jeffrey B Kopp; Jiang He; Nancy G Jensvold; Kaixiang Tao; Michael S Lipkowitz; Lawrence J Appel
Journal:  N Engl J Med       Date:  2013-11-09       Impact factor: 91.245

3.  Genotype-based changes in serum uric acid affect blood pressure.

Authors:  Afshin Parsa; Eric Brown; Matthew R Weir; Jeffrey C Fink; Alan R Shuldiner; Braxton D Mitchell; Patrick F McArdle
Journal:  Kidney Int       Date:  2011-12-21       Impact factor: 10.612

Review 4.  Uric acid and chronic kidney disease: which is chasing which?

Authors:  Richard J Johnson; Takahiko Nakagawa; Diana Jalal; Laura Gabriela Sánchez-Lozada; Duk-Hee Kang; Eberhard Ritz
Journal:  Nephrol Dial Transplant       Date:  2013-03-29       Impact factor: 5.992

Review 5.  Urate transporters in the genomic era.

Authors:  Hiroyuki Sakurai
Journal:  Curr Opin Nephrol Hypertens       Date:  2013-09       Impact factor: 2.894

6.  Hyperuricemia causes glomerular hypertrophy in the rat.

Authors:  Takahiko Nakagawa; Marilda Mazzali; Duk-Hee Kang; John Kanellis; Susumu Watanabe; Laura G Sanchez-Lozada; Bernardo Rodriguez-Iturbe; Jaime Herrera-Acosta; Richard J Johnson
Journal:  Am J Nephrol       Date:  2003 Jan-Feb       Impact factor: 3.754

7.  Mild hyperuricemia induces glomerular hypertension in normal rats.

Authors:  Laura G Sánchez-Lozada; Edilia Tapia; Carmen Avila-Casado; Virgilia Soto; Martha Franco; José Santamaría; Takahiko Nakagawa; Bernardo Rodríguez-Iturbe; Richard J Johnson; Jaime Herrera-Acosta
Journal:  Am J Physiol Renal Physiol       Date:  2002-11

8.  Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy.

Authors:  J Syrjänen; J Mustonen; A Pasternack
Journal:  Nephrol Dial Transplant       Date:  2000-01       Impact factor: 5.992

9.  Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects.

Authors:  K Iseki; S Oshiro; M Tozawa; C Iseki; Y Ikemiya; S Takishita
Journal:  Hypertens Res       Date:  2001-11       Impact factor: 3.872

10.  A role for uric acid in the progression of renal disease.

Authors:  Duk-Hee Kang; Takahiko Nakagawa; Lili Feng; Susumu Watanabe; Lin Han; Marilda Mazzali; Luan Truong; Raymond Harris; Richard J Johnson
Journal:  J Am Soc Nephrol       Date:  2002-12       Impact factor: 10.121

View more
  22 in total

Review 1.  Mendelian Randomization as an Approach to Assess Causality Using Observational Data.

Authors:  Peggy Sekula; Fabiola Del Greco M; Cristian Pattaro; Anna Köttgen
Journal:  J Am Soc Nephrol       Date:  2016-08-02       Impact factor: 10.121

2.  Uric Acid and the Risks of Kidney Failure and Death in Individuals With CKD.

Authors:  Anand Srivastava; Arnaud D Kaze; Ciaran J McMullan; Tamara Isakova; Sushrut S Waikar
Journal:  Am J Kidney Dis       Date:  2017-11-11       Impact factor: 8.860

3.  Uric acid is not associated with decline in renal function or time to renal replacement therapy initiation in a referred cohort of patients with Stage III, IV and V chronic kidney disease.

Authors:  Hakan Nacak; Merel van Diepen; Abdul R Qureshi; Juan J Carrero; Theo Stijnen; Friedo W Dekker; Marie Evans
Journal:  Nephrol Dial Transplant       Date:  2015-07-16       Impact factor: 5.992

Review 4.  Time to target uric acid to retard CKD progression.

Authors:  Takanori Kumagai; Tatsuru Ota; Yoshifuru Tamura; Wen Xiu Chang; Shigeru Shibata; Shunya Uchida
Journal:  Clin Exp Nephrol       Date:  2016-06-23       Impact factor: 2.801

5.  Weak Association Between Genetic Markers of Hyperuricemia and Cardiorenal Outcomes: Insights From the STANISLAS Study Cohort With a 20-Year Follow-Up.

Authors:  Mehmet Kanbay; Constance Xhaard; Edith Le Floch; Claire Dandine-Roulland; Nicolas Girerd; João Pedro Ferreira; Jean-Marc Boivin; Sandra Wagner; Delphine Bacq-Daian; Jean-François Deleuze; Faiez Zannad; Patrick Rossignol
Journal:  J Am Heart Assoc       Date:  2022-04-26       Impact factor: 6.106

Review 6.  Uric acid in the pathogenesis of metabolic, renal, and cardiovascular diseases: A review.

Authors:  Usama A A Sharaf El Din; Mona M Salem; Dina O Abdulazim
Journal:  J Adv Res       Date:  2016-12-03       Impact factor: 10.479

Review 7.  Asymptomatic hyperuricemia and chronic kidney disease: Narrative review of a treatment controversial.

Authors:  Theodoros Eleftheriadis; Spyridon Golphinopoulos; Georgios Pissas; Ioannis Stefanidis
Journal:  J Adv Res       Date:  2017-05-05       Impact factor: 10.479

Review 8.  Serum uric acid levels and multiple health outcomes: umbrella review of evidence from observational studies, randomised controlled trials, and Mendelian randomisation studies.

Authors:  Xue Li; Xiangrui Meng; Maria Timofeeva; Ioanna Tzoulaki; Konstantinos K Tsilidis; John PA Ioannidis; Harry Campbell; Evropi Theodoratou
Journal:  BMJ       Date:  2017-06-07

Review 9.  Urate Transporters in the Kidney: What Clinicians Need to Know.

Authors:  Sungjin Chung; Gheun-Ho Kim
Journal:  Electrolyte Blood Press       Date:  2021-06-30

Review 10.  Management of Chronic Kidney Disease: The Relationship Between Serum Uric Acid and Development of Nephropathy.

Authors:  Christian Mende
Journal:  Adv Ther       Date:  2015-12-09       Impact factor: 3.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.